A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors.

Grail's Galleri multi-cancer early detection test missed its primary endpoint in a landmark NHS trial but still has a pathway to FDA approval and insurer coverage. Management points to favorable trends in detecting 12 deadly cancers, upcoming 12-month follow-up data, and strong positive predictive values as reasons for optimism. The stock's future depends on FDA decisions and insurer cost-benefit analyses.